Drugs that help lower blood pressure may reduce the risk of early death for people with advanced kidney disease, a new study finds. The drugs could also lower patients' odds of requiring dialysis, the researchers said. The new study out ...
Exercise might help breast cancer survivors relieve the joint pain that is a side effect of their medications, researchers say. A new study included patients who were taking aromatase inhibitor drugs, such as Arimidex (anastrozole), ...
Tags: exercise, breast cancer, relieve the joint pain, breast cancer survivors
When it comes to easing the side effects of certain breast cancer drugs, acupuncture may work no better than a "sham" version of the technique, a small trial suggests. Breast cancer drugs known as aromatase inhibitors often cause side ...
Tags: breast cancer, breast cancer drugs, acupuncture, women health
Gilead Sciences has received notice of compliance from Health Canada for its once-daily oral nucleotide analog polymerase inhibitor Sovaldi or sofosbuvir 400mg tablets for the treatment of chronic hepatitis C or CHC infection. Sovaldi is ...
BIND Therapeutics, a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, has amended its development and commercialization collaboration agreement with Amgen to extend the period ...
Baxter International has filed an application to the US Food and Drug Administration (FDA) for a pediatric indication for Rixubis [Coagulation Factor IX (Recombinant)] to treat hemophilia B. The submission was based on a Phase II/III ...
Covagen has announced that the company has secured CHF42m in a tranched Series B financing with an option to obtain an additional CHF14m that would increase the total amount of the financing round to CHF56m. This financing will mainly ...
The U.S. Food and Drug Administration approved Sovaldi -- sofosbuvir -- to treat chronic hepatitis C virus infection without interferon, officials say. Dr. Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center ...
Tags: FDA, Sovaldi, sofosbuvir, chronic hepatitis C, health
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved Sovaldi (sofosbuvir) 400mg tablets, a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (CHC) infection ...
Tags: Gilead Sciences, Chronic Hepatitis
The US Food and Drug Administration (FDA) has granted orphan drug status for Kinex Pharmaceuticals' dual src/pre-tubulin inhibitor 'KX02' for the treatment of gliomas, which are the most common and aggressive form of brain cancer. KX02 is ...
Tags: Orphan Drug, Medicine
The US Food and Drug Administration (FDA) has granted orphan drug designation to Conatus Pharmaceuticals' drug candidate emricasan for the treatment of liver transplant patients with reestablished fibrosis to delay the progression to ...
Eisai has filed an application for the proton pump inhibitor Pariet in Japan looking for a further indication expansion for use in the prevention of recurrent gastric or duodenal ulcer caused by low-dose aspirin therapy as well as the ...
The European Medicines Agency (EMA) has fully validated and granted accelerated assessment to Boehringer Ingelheim's application for European marketing authorization of faldaprevir, a potent second generation oral protease inhibitor. ...
Germany-based Bayer HealthCare and US-based Onyx Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved Nexavar (sorafenib), an oral multi-kinase inhibitor, for the treatment of patients with ...
European Medicines Agency's (EMA) the Committee for Medicinal Products for Human Use (CHMP) has issued positive opinion for AstraZeneca and Bristol-Myers Squibb's of Xigduo for adults aged 18 and older with type 2 diabetes mellitus. The ...